To screen ETFs by asset class, performance, yield and more, check out the ETF Hub. Seeking Alpha, 4 hours ago
PDUFA date approaches for Xiaflex label expansion - Seeking Alpha, 1 week ago
PDUFA date approaches for Lymphoseek expanded label - Seeking Alpha, 1 week ago
News Editor Nano cap AEterna Zentaris (AEZS -19.8%) plummets on a 3x surge in volume. Shares are down 42% from the September 2 peak of $1.54 and 34% from Friday's close of $1.34. The last three down moves have been on higher volume. November 5 ...Seeking Alpha, 1 week ago
Salix Pharmaceuticals : TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea
Study Results Presented at the American College of Gastroenterology (ACG) Scientific Meeting in Philadelphia on October 21 st Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that Dr. Anthony Lembo of Beth Israel ...4 Traders, 9 hours ago Salix Pharmaceuticals, Ltd.???s TARGET 3 Study Examines The Safety And Efficacy Of Repeat Treatment With Rifaximin 550 mg For Irritable Bowel Syndrome With Diarrhea BioSpace, 2 hours ago Salix's TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea TMC Net, 8 hours ago
lenvatinib Treatment for Thyroid Cancer Tokyo -- October 15, 2014 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application ...Drugs.com, 12 hours ago U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome Stockwatch, 6 days ago FDA Accepts Pfizer's Palbociclib New Drug Application for Priority Review PharmaceuticalProcessing, 6 days ago Pfizer's NDA for Palbociclib accepted for US FDA's priority review for first-line therapy in combination with letrozole in postmenopausal women with breast cancer PredictWallStreet, 1 week ago
SAN DIEGO "The FDA Office of Orphan Products Development (OOPD) evaluates scientific and clinical data submissions from sponsors to identify and designate drug candidates that could potentially treat rare diseases to help advance the evaluation ...Bio-Medicine, 17 hours ago Horizon Pharma's Actimmune Gets Orphan Drug Designation - Analyst Blog Zacks.com, 2 weeks ago Orphan status for Horizon Pharma's Actimmune in Friedreich's ataxia04-10-2014 Pharma Letter, 2 weeks ago MABVAX THERAPEUTICS : Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma 4 Traders, 2 weeks ago
Valeant Pharmaceuticals International's (VRX) CEO Mike Pearson on Q3 2014 Results - Earnings Call Transcript
Operator Good morning. My name is Keith, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Valeant Third Quarter 2014 Earnings Conference Call. All lines have been placed on mute to prevent any ...Seeking Alpha, 23 hours ago
While Friday was a welcome relief for shell-shocked stock investors, much of the damage that has been inflicted since the start of the quarter is still weighing on some top biotech stocks. A new report from Merrill Lynch highlights five biotechs ...24/7 Wall St, 1 day ago
Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo nivolumab in Combination with Targeted Therapies from Novartis to Treat Non-Small...
Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo nivolumab in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer NSCLC By a News Reporter-Staff News Editor at Pharma Business Week Bristol-Myers ...Pharmacy Choice, 1 day ago BMS Withdraws Combination NDA, Vows to Pursue Daclatasvir Approval Genetic Engineering News, 2 weeks ago BMS Launches Cancer-Combo Collaborations with Novartis, MD Anderson Genetic Engineering News, 2 weeks ago Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies Morningstar.com, 2 weeks ago
2014 may be approaching its conclusion but there is a catalogue of key events set to occur among the large cap pharmaceutical and biotech players over the next two and half months. Monday ( October 20 ) could see Novo Nordisk gain approval for ...FirstWord Pharma, 2 days ago
Amarantus Bioscience Holdings, a biotechnology company focussed on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and ophthalmological disorders, announced that it has applied to the US Food & Drug ...PharmaBiz, 3 days ago Amarantus Bioscience Holdings, Inc. (AMBS: OTCQB) | Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa Pink Sheets, 5 days ago Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa Pettinga Financial Advisors, 5 days ago Amarantus BioSciences, Inc. Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa BioSpace, 5 days ago
on your WebpageAdd Widget >Get your members hooked!